title: Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma.
abstract: OBJECTIVE
  We developed and evaluated a regimen including fotemustine, teniposide and dexamethasone (FTD) for treating patients with central nervous system (CNS) lymphoma based on pharmacokinetic properties of individual agents and in combination.
  
  
  METHODS
  In a comparison study, 8 patients with primary CNS lymphoma (PCNSL) and 8 with secondary CNS lymphoma (SCNSL) were treated with FTD (comprising fotemustine 100 mg/m2, 1h infusion, day 1; teniposide 60 mg/m2, >0.5 h infusion, on day 2, 3, 4; dexamethasone 40 mg, 1h infusion, on day 1, 2, 3, 4 and 5; and methotrexate 12 mg, cytosine arabinoside 50 mg plus dexamethasone 5 mg intrathecally, on day 2 and 7). Cycles were repeated every 3 weeks. After response assessment, patients received whole brain radiotherapy.
  
  
  RESULTS
  Of the 8 PCNSL patients, 4 (50%) achieved CR and 3 (38%) PR, an overall response rate of 88%. Four patients (50%) were in continuing remission at the end of this study after a median follow-up of 30 months (range 10 to 56 months). Of the 8 SCNSL patients the overall response rate was 63% (CR+PR:38%+25%). All responses were achievable with predictable toxicity mainly reflecting reversible myelosuppression.
  
  
  CONCLUSIONS
  This study suggests that FTD could be an effective treatment for CNS lymphoma, and is worthy of further evaluation.
authors: Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China E-mail : mingzhi_zhang12345@163.com.
authors: Jing-Jing
authors: JJ
authors: Wu
authors: Xin-Hua
authors: XH
authors: Wang
authors: Ling
authors: L
authors: Li
authors: Xin
authors: X
authors: Li
authors: Lei
authors: L
authors: Zhang
authors: Zhen-Chang
authors: ZC
authors: Sun
authors: Xiao-Rui
authors: XR
authors: Fu
authors: Wang
authors: W
authors: Ma
authors: Yu
authors: Y
authors: Chang
authors: Xu-Dong
authors: XD
authors: Zhang
authors: Li-Juan
authors: LJ
authors: Han
authors: Ming-Zhi
authors: MZ
authors: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D009943:Organophosphorus Compounds / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant / Q000379:methods; D013713:Teniposide / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D003561:Cytarabine; D003907:Dexamethasone; D013713:Teniposide; C054368:fotemustine; D008727:Methotrexate